Chemicalinfo Chemlink Pharm-Chem Net

Cancer News Article ord=Math.random()*10000000000000000;document.write('');Sprycel® Effective for CNS Philadelphia Chromosome-...

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma Donna E. Reece,* Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mikhael, Mariela Pantoja, Wei Xu, an...

Cipla eyeing copies of 20 patented drugsDrug maker obtains similar-sounding trademarks for copycat versions of at least five global drug giantsMumbai: Cipla Ltd, India’s second largest drug maker by sales, may launch copycat versions of 20 pate...

Cyclacel Publishes Study of Seliciclib Synergy with Tarceva(Erlotinib) and Herceptin in Journal Clinical Cancer Research -- Increased Antitumor Activity and Molecular Mechanism Explored -- BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuti...

FDA MedWatch- Avastin (bevacizumab) and Sunitinib Malate- Reports of Microangiopathic Hemolytic Anemia In Patients Treated With This Combination ROCKVILLE, Md., July 14, 2008--Genentech, Inc. informed healthcare professionals of reports of sever...

最近美国临床药理和治疗学协会一个研究表明：在进食中服用，而不是空腹条件下，服用昂贵的治疗乳腺癌药物-拉帕替尼(Lapatinib)，能提高机体对药物吸收，降低治疗所需的药物剂量，能为患者大大减少治疗费用。在进食时服用500毫克的拉帕替尼能得到与空腹时服用1250毫克的拉帕替尼相同的治疗效果。

Infinity Pharmaceuticals Named as One of the Best Places to WorkInfinity's President of Research and Development Julian Adams, Ph.D. Named as One of the Most Influential People in Life Sciences Last update: 8:33 a.m. EDT July 9, 2008CAMBRIDGE, Mass.,...

Indian Patent office to hear drug firms` views before granting licence The Indian patent office will provide drug innovators a chance to explain their views before a decision to grant compulsory licences against their patented medicines is taken. The...

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)This study has been terminated. Sponsored by: Scherin...

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer (HORIZON II)This study is currently recruiting participants. Verified by AstraZeneca, June 2008 Sponsored...